SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Hepatitis C fact sheet, no. 164. http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Revised June 2011. Accessed November 2011.
  • 2
    Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
  • 3
    Awad T, Thorlund K, Hauser G, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: a systematic review of randomized trials. HEPATOLOGY 2010; 51: 1176-1184.
  • 4
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
  • 5
    McHutchison J, Manns M, Muir A, Terrault N, Jacobson I, Afdhal N, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292.
  • 6
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  • 7
    Poordad F, McCone JrJ, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 8
    Pawlotsky JM. Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus. HEPATOLOGY 2011; 53: 1742-1751.
  • 9
    Reddy R, Rodriguez-Torres M, Gane E, Robson R, Lalezari J, Everson GT, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. HEPATOLOGY 2007; 46( Suppl 1): 862A.
  • 10
    Gane EJ, Rodriguez-Torres M, Nelson DR, Jacobson IM, McHutchison JG, Jeffers L, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. HEPATOLOGY 2008; 48: 1024A.
  • 11
    Rodriguez-Torres M, Lalezari J, Gane EJ, De Jesus E, Nelson DR, Everson GT, et al. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with peg-IFN and ribavirin: subanalysis by race/ethnicity, weight, and HCV genotype. HEPATOLOGY 2008; 48: 1160A.
  • 12
    Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan J, et al. RG7128 alone or in combination with pegylated interferon- 2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202: 1510-1519.
  • 13
    Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor -d-2-deoxy-2-fluoro-2-C-methylcytidine (PSI-6130) and identification of a novel active 5-triphosphate species. J Biol Chem 2007; 282: 29812.
  • 14
    Guedj J, Rong L, Dahari H, Perelson A. A perspective on modelling hepatitis C virus infection. J Viral Hepat 2010; 17: 825-833.
  • 15
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
  • 16
    Shudo E, Ribeiro RM, Talal AH, Perelson AS. A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 2008; 13: 919-926.
  • 17
    Guedj J, Perelson AS. HCV RNA declines during antiviral therapy with a second phase rate that increases with drug effectiveness: implications for treatment duration HEPATOLOGY 2011; 53: 1801-1808.
  • 18
    Holford N, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982; 16: 143-166.
  • 19
    Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005; 49: 1020-1038.
  • 20
    Pinheiro J, Bates D. Mixed-Effects Models in S and S-PLUS. New York: Springer Verlag, 2000.
  • 21
    Adiwijaya B, Hare B, Caron P, Randle J, Neumann A, Reesink H, et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther 2009; 14: 591-595.
  • 22
    Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974; 19: 716-723.
  • 23
    Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJF, Jagannatha S, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients. HEPATOLOGY 2011; 54: 50-59.
  • 24
    Dahari H, Guedj J, Rong L, Nettles RE, Perelson AS. Higher hepatitis C virus (HCV) clearance rates during treatment with direct acting agents compared to interferon-alpha [Abstract]. HEPATOLOGY 2010; 52: 121A.
  • 25
    Lawitz E, Rodriguez-Torres M, Denning J, Cornpropst M, Clemons D, Mcnair L, et al. Once daily dual-nucleotide combination of PSI-938 and PSI-977 provides 94% HCV RNA<lod at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). J Hepatol 2011; 54: S543.
  • 26
    Furman PA, Wang P, Niu C, Bao D, Symonds W, Nagarathnam D, et al. PSI-7851: a novel liver-targeting nucleotide prodrug for the treatment of hepatitis C [Abstract]. HEPATOLOGY 2009; 48: 1161A.
  • 27
    Dahari H, Shudo E, Cotler SJ, Layden TJ, Perelson AS. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther 2009; 14: 459-464.
  • 28
    Dahari D, Layden-Almer JE, Kallwitz E, Ribeiro RM, Cotler SJ, Layden TJ, et al. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology 2009; 136: 1402-1409.
  • 29
    Mihm U, Welker M, Teuber G, Wedemeyer H, Berg T, Breske A, et al. HCV viral kinetics during ribavirin monotherapy: results of a randomized partially double blind placebo controlled clinical trial. J Hepatol 2011; 54( Suppl): S185-S185.
  • 30
    Dahari H, Lo A, Ribeiro RM, Perelson AS. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 2007; 247: 371-381.
  • 31
    Guedj J, Neumann AU. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 2010; 267: 330-340.
  • 32
    Dahari D, Guedj J, Rong L, Nettles RE, Cotler SJ, Layden JE, et al. New insights into the mechanisms of action of interferon-alpha and BMS-790052: a multi-scale mathematical modeling approach J Hepatol 2011; 54( Suppl): S474.
  • 33
    Jensen D, Wedemeyer H, Herring R, Ferenci P, Ma M, Zeuzem S. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: planned week 12 interim analysis from the PROPEL study [Abstract]. HEPATOLOGY 2010; 52: A81.
  • 34
    Pockros PJ, Jensen D, Tsai N, Taylor RM, Ramji A, Cooper C, et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. J Hepatol 2011; 54( Suppl): S538.
  • 35
    Gane E, Roberts S, Stedman C, Angus P, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.